Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505)

Deirdre R. Pachman, Rui Qin, Drew Seisler, Ellen M.Lavoie Smith, Suneetha Kaggal, Paul Novotny, Kathryn J. Ruddy, Jacqueline M. Lafky, Lauren E. Ta, Andreas S. Beutler, Nina D. Wagner-Johnston, Nathan P. Staff, Axel Grothey, Patrick M. Dougherty, Guido Cavaletti, Charles L. Loprinzi

Research output: Contribution to journalArticle

28 Scopus citations

Abstract

Purpose: Oxaliplatin and paclitaxel are commonly used chemotherapies associated with acute and chronic neuropathies. There is a need to better understand the similarities and differences of these clinical syndromes. Methods: Neuropathy data were pooled from patients receiving adjuvant oxaliplatin and weekly paclitaxel or every 3 weeks of paclitaxel. Patients completed daily questionnaires after each chemotherapy dose and the European Organization for Research and Treatment of Cancer quality-of-life questionnaire for patients with chemotherapy-induced peripheral neuropathy before each chemotherapy cycle and for 12 months post-treatment. Results: Acute neuropathy symptoms from both drugs peaked around day 3. Acute symptoms experienced in cycle 1 predicted occurrence in subsequent cycles. Paclitaxel-induced acute symptoms were similar in intensity in each cycle and largely resolved between cycles. Oxaliplatin-induced acute symptoms were about half as severe in the first cycle as in later cycles and did not resolve completely between cycles. Both drugs caused a predominantly sensory chronic neuropathy (with numbness and tingling being more common than pain). Oxaliplatin-induced neuropathy worsened after the completion of treatment and began to improve 3 months post-treatment. In contrast, paclitaxel-induced neuropathy began improving immediately after chemotherapy cessation. During treatment, the incidence of paclitaxel sensory symptoms was similar in the hands and feet; with oxaliplatin, the hands were affected more than the feet. Both paclitaxel- and oxaliplatin-induced acute neurotoxicity appeared to predict the severity of chronic neuropathy, more prominently with oxaliplatin. Conclusions: Knowledge of the similarities and differences between neuropathy syndromes may provide insight into their underlying pathophysiology and inform future research to identify preventative treatment approaches.

Original languageEnglish (US)
Pages (from-to)5059-5068
Number of pages10
JournalSupportive Care in Cancer
Volume24
Issue number12
DOIs
StatePublished - Dec 1 2016

Keywords

  • Chemotherapy-induced peripheral neuropathy
  • Oxaliplatin neuropathy
  • Paclitaxel neuropathy

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505)'. Together they form a unique fingerprint.

  • Cite this

    Pachman, D. R., Qin, R., Seisler, D., Smith, E. M. L., Kaggal, S., Novotny, P., Ruddy, K. J., Lafky, J. M., Ta, L. E., Beutler, A. S., Wagner-Johnston, N. D., Staff, N. P., Grothey, A., Dougherty, P. M., Cavaletti, G., & Loprinzi, C. L. (2016). Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505). Supportive Care in Cancer, 24(12), 5059-5068. https://doi.org/10.1007/s00520-016-3373-1